Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2173603 | 0.91 | SGMS1 (0.49) | TRPV1LMNASGMS1HIF1ASMN1; SMN2 | |
| SCHEMBL283213 | 0.90 | TRPV1 (0.58) | TRPV1LMNASGMS1HIF1ANPC1 | |
| SCHEMBL12407097 | 0.90 | TRPV1 (0.45) | TRPV1SGMS1HIF1ASMN1; SMN2MEN1 | |
| SCHEMBL4387708 | 0.89 | TRPV1 (0.44) | TRPV1LMNAHIF1AALDH1A1NPC1 | |
| SCHEMBL4387635 | 0.85 | SGMS1 (0.47) | TRPV1LMNASGMS1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2172869 | 0.85 | CYP1A2 (0.43) | TRPV1SGMS1HIF1AALDH1A1SMN1; SMN2 | |
| SCHEMBL4397607 | 0.85 | CYP1A2 (0.46) | TRPV1LMNASGMS1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4396904 | 0.85 | MAPT (0.48) | TRPV1LMNASGMS1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4392420 | 0.85 | CYP1A2 (0.52) | VNN1LMNASGMS1ALDH1A1NPC1 | |
| SCHEMBL5670058 | 0.84 | TRPV1 (0.45) | TRPV1VNN1GPR52LMNASGMS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2009-07-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186905-A1 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | ALK, BCL3, MCL1 | TRPV1 3477/4885VNN1 4305/4885GPR52 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.